Background: Androgen deprivation therapy (ADT) by surgical or medical castration is recommended for advanced or metastatic prostate cancer. Recent literature suggests that medical castration by luteinizing hormone receptor hormone (LHRH) antagonists might have advantages over treatment with LHRH agonists in patients with metastatic prostate cancer when prostate specific antigen (PSA) progressio...

Background. Most patients with metastatic prostate cancer are endocrinologically treated with LHRH agonist, but finally castration-refractory and hormone-refractory cancers occur. Serum testosterone levels get low to "the castration level" by LHRH agonists but may not get low enough against castration-refractory prostate cancer. Methods. As case series, twelve patients suffering from hormone-re...

The present study was aimed to examine the possible functional relationship between melatonin and hypothalamic transmitters, endogenous opioids and excitatory amino acids in controlling gonadotropin secretion in ovariectomized estrogen-primed rats. An intravenous injection of naloxone (mu opioid receptor antagonist), N-methyl-D-aspartate (NMDA; NMDA receptor agonist) or luteinizing hormone-rele...

Protein tyrosine kinases regulate numerous signal transduction pathways, including those controlling cell growth [l] . Apart from the growth factor receptor tyrosine kinases, certain G proteincoupled receptors also are capable of stimulating protein tyrosine phosphorylations in their target cells [2]. Another group of protein kinases that become activated in response to various extracellular st...

The luteinizing hormone-releasing hormone (LHRH) agonist ICI 118630 was found to increase testosterone production in purified rat testis Leydig cells in a concentration- and time-dependent manner, but no consistent changes in cyclic AMP levels were detectable. The stimulation of steroidogenesis by LHRH agonist was found to be dependent on the concentration of Ca2+ in the incubation medium; at l...

The ovary is the major site of oestrogen production in premenopausal women. Removal of the ovaries in premenopausal patients with breast cancer has long been recognised to potentially alter the course of disease. This procedure leads to a marked reduction in the circulating levels of oestrogen. It has been shown that ovariectomy given as an adjuvant treatment reduces the odds of recurrence or d...

Objectives: The aim of this study was to examine the efficacy and toxicity between luteinising hormone releasing hormone analogue (LHRH-a) therapy and maximal androgen blockade (MAB) therapy in patients with advanced prostate cancer in China. Materials and methods: A total of 392 patients with advanced prostate cancer were included in the study. Patients who received LHRH-a therapy were include...

A male patient with hypogonadotropic hypogonadism has been treated by pulsatile administration lf luteinizing hormone-releasing hormone (LHRH) (20-25 micrograms, every 2 hours, sc) for 4 years 6 months. His plasma testosterone (T) concentration began to increase after 4 weeks of treatment and reached the normal range in week 5. He showed complete secondary sexual development after 1 year of tre...

Oral delivery of peptide and protein drugs has potential advantages for the aquaculture industry. The bioavailability of proteins and peptides from the intestinal tract is very low. This can be attributed in part to the proteolytic activities of the intestine. Bovine serum albumin (BSA), human (hLHRH) and salmon (sLHRH) luteinizing-hormone releasing hormones were used to evaluate the proteolyti...

BACKGROUND Oncological results of radiotherapy for locally advanced prostate cancer (PC) are significantly improved by simultaneous application of LHRH analoga (e.g. goserelin). As 85% of PC express LHRH receptors, we investigated the interaction of goserelin incubation with radiotherapy under androgen-deprived conditions in vitro. METHODS LNCaP and PC-3 cells were stained for LHRH receptors....